A journey to witness China’s biotech boom up close
2 October 2026 · filed under 55a5b371dd56
STAT News correspondent Jason Mast traveled to Shanghai to report firsthand on China’s biotechnology sector, which STAT describes as now producing roughly half of the drugs in the global development pipeline. The resulting account, published October 1 as part of STAT’s subscriber coverage, examines the competitive landscape that has drawn concern among American drug developers and policymakers.
According to the summary provided by STAT, the piece centers on direct observation of Chinese biotech activity rather than remote analysis, with Mast traveling to the region to assess the scale and pace of drug development there. The outlet frames this growth in the Chinese pipeline as a factor reshaping competitive dynamics in the global pharmaceutical industry, with American companies and observers described as increasingly attentive to the pace of Chinese output.
No further detail on methodology, specific companies visited, or the mechanisms behind the reported pipeline growth is available in the material provided. The report is published behind STAT’s subscription paywall, limiting independent verification of its specific findings and claims beyond the summary and headline framing supplied by the outlet.
Readers seeking the full scope of Mast’s on-the-ground reporting, including any named companies, officials, or laboratories, should consult STAT News directly, as the source material furnished for this bulletin does not itself specify those particulars.